TxCell To Present An Innovative, Personalized Cell-Based Immunotherapy Approach At The 16th Biotechnology Industry Organization (BIO) CEO & Investor Conference 2014, New York, U.S.A.
Published: Feb 05, 2014
Valbonne, France, February 5 2014. – TxCell SA, a clinical stage biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that Damian Marron, CEO, TxCell, will present at BIO CEO & Investor Conference 2014. The conference will take place on February 10 - 11, 2014 in New York City, USA. An overview of the company, its clinical developments and milestones will be provided.
TxCell’s corporate presentation is scheduled for Tuesday, February 10, 2014 at 10:15 a.m. PT at the Park South of the Waldorf Astoria Hotel, 301 Park Avenue, New York, NY 10022.
The Company will discuss its unique personalized technology platform, ASTrIA. The platform is based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs) for treating severe, chronic autoimmune inflammatory diseases. The review will include the latest clinical data of Ovasave®, TxCell lead product candidate in refractory Crohn’s disease, currently in phase II development. There are 100,000 sufferers of refractory Crohn’s disease in the 7 major markets1.
Additional information will be disclosed about the recently announced entry into full development of Col-Treg, TxCell’s second product candidate for the treatment of Autoimmune Uveitis, a rare disease causing blindness. Autoimmune Uveitis causes 10 – 15% of legal blindness in the developed world and 30,000 new cases of blindness per year in the US alone2. Details of the Company’s projects for 2014 will also be provided.
1According to PharMetrics Analysis, September 2008
2According to GlobalData Report GDHC008POA-Dec. 2013
TxCell is developing innovative personalized cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary ASTrIA technology platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has completed a phase I/IIa study of its lead product candidate, Ovasave® in refractory Crohn’s disease patients and has reported good tolerability and positive signals of efficacy. The company plans to initiate a phase IIb study in the same patient population. TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. The company has 38 employees based at its headquarters and at its manufacturing site in Besançon.
For more information, please visit www.txcell.com
Help employers find you! Check out all the jobs and post your resume.